NVCT insider transaction filings
Nuvectis Pharma, Inc. — 25 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen NVCT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Carson Michael J. — Vice President, Finance | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2026-07-01 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 50,000 @ $18.32 | EDGAR |
| 2026-07-01 | 4 | BENTSUR RON — Chairman & CEO, Director, 10% owner | Purchase (P): 12,500 @ $20 | EDGAR |
| 2026-06-12 | 4 | Sanchez Juan — Director | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2026-06-12 | 4 | Kaplan Matthew L. — Director | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2026-06-12 | 4 | Hoberman Kenneth — Director | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2026-06-12 | 4 | Oliviero James F III — Director | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2026-01-09 | 4 | Shemesh Shay — Chief Dev. & Ops. Officer | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-01-09 | 4 | Poradosu Enrique — Chief Science & Business Off | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-01-09 | 4 | Carson Michael J. — Vice President, Finance | Grant/award (A): 61,200 @ $0 | EDGAR |
| 2026-01-09 | 4 | BENTSUR RON — Chairman & CEO, Director, 10% owner | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-11-06 | 4 | Sanchez Juan — Director | Purchase (P): 13,000 @ $5.79 | EDGAR |
| 2025-11-06 | 4 | Kaplan Matthew L. — Director | Purchase (P): 11,000 @ $5.84 | EDGAR |
| 2025-11-06 | 4 | BENTSUR RON — Chairman & CEO, Director, 10% owner | Purchase (P): 5,000 @ $5.72 | EDGAR |
| 2025-10-31 | 4 | Sanchez Juan — Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2025-10-29 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 46,900 @ $6.06 · Purchase (P): 35,034 @ $6.15 · Purchase (P): 72,836 @ $6.28 | EDGAR |
| 2025-06-24 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 5,603 @ $7.99 | EDGAR |
| 2025-06-20 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 5,399 @ $8.11 · Purchase (P): 28,043 @ $8.05 | EDGAR |
| 2025-06-12 | 4 | Kaplan Matthew L. — Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2025-06-12 | 4 | Hoberman Kenneth — Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2025-06-12 | 4 | Oliviero James F III — Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2025-05-13 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 21,167 @ $8.11 | EDGAR |
| 2025-05-12 | 4/A | Mosseri Marlio Charles — 10% owner | Purchase (P): 100 @ $8.99 · Purchase (P): 100 @ $8.71 · Purchase (P): 2,400 @ $8.97 · Purchase (P): 9,850 @ $8.95 · Purchase (P): 9,817 @ $8.90 · Purchase (P): 5,395 @ $8.98 | EDGAR |
| 2025-05-09 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 2,340 @ $8.40 · Purchase (P): 10,104 @ $8.64 · Purchase (P): 2,703 @ $8.40 · Purchase (P): 9,614 @ $8.64 · Purchase (P): 50 @ $8.65 · Purchase (P): 100 @ $8.65 · +2 more | EDGAR |
| 2025-02-11 | 4 | Mosseri Marlio Charles — 10% owner | Purchase (P): 240,000 @ $5 | EDGAR |
Recent 8-K events — Nuvectis Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NVCT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →